Clinical Trial Update: A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE) [Phase 3]

View source ↗

Summary

Open-label extension study assessing safety and tolerability of rhPTH (1-84) for adults with hypoparathyroidism; completed Phase 3 trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoparathyroidism

Drugs mentioned

• NPSP558

Snippet

Sponsor: Shire | Conditions: Hypoparathyroidism | Phase 3 | Status: COMPLETED | Results posted: 2019-08-06